Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (284)	7/9/2003 10:58:32 AM
From: keokalani'nui	Respond to of 824

Old news. But not sure what the erratum says. Lancet. 2002 Sep 21;360(9337):923-4. Related Articles, Links Erratum in: Lancet 2002 Dec 21-28;360(9350):2090. Rituximab for idiopathic membranous nephropathy. Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P. Ospedali Riuniti Di Bergam, Unit of Nephrology and Dialysis, Aldo and Cele Dacco Clinical Research Centre for Diseases, Mario Negri Institute for Parmacological Research, Via Gavazzeni 1124125, Bergamo, Italy. gremuzzi@marionegri.it Treatments for idiopathic membranous nephropathy, a common cause of nephrotic syndrome, can be very toxic. In view of the pathogenic potential of B cells in this disease, we studied the effects of four weekly infusions of rituximab (375 mg/m(2)-- the monoclonal antibody to B-cell antigen CD20--in eight patients who had idiopathic membranous nephropathy with persistent nephrotic syndrome. At weeks 4 and 20, urinary protein decreased from mean (SE) 8.6 g/24 h (1.4) to 3.8 (0.8) and 3.7 (0.9), respectively (p<0.0001). At week 20, albuminuria and albumin fractional clearance decreased by 70% and 65%, and serum albumin increased by 31%. CD20 B lymphocytes fell below normal ranges up to study end. The short-term risk-benefit profile of rituximab seems more favourable to that of any other immunosuppressive drug used to treat idiopathic membranous nephropathy.

To: Icebrg who wrote (284)	7/17/2003 7:46:33 AM
From: Icebrg	Read Replies (2) \| Respond to of 824

Alexion Antibody Technologies It seems they are (slowly, slowly) upgrading their website. It is in its current status available at alxnsd.com Among the still relatively few wares on offer is a reprint from a magazine article of last year dealing with their Recombinant Antibody Technologies. alxnsd.com Not that I left the computer much wiser, but it seems relatively advanced what they do. They are not only creating fully human antibodies, but they are evidently taking one (or even two) steps further by manipulating these antibodies.